Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium

International Journal of Gynecological Pathology

Volumn 23, Issue 4, 2004, Pages 321-329

  Cao, Q Jackie ^a,b   Belbin, Thomas ^a   Socci, Nicholas ^a   Balan, Raluca ^a   Prystowsky, Michael B ^a   Childs, Geoffrey ^a   Jones, Joan G ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

cDNA microarrays; Endometrial carcinoma; Endometrioid; Serous

Indexed keywords

ACETYL COENZYME A ACETYLTRANSFERASE; APOLIPOPROTEIN; CATENIN; COLLAGEN TYPE 1; COMPLEMENTARY DNA; CYSTEINE PROTEINASE INHIBITOR; DESMOPLAKIN; ELONGATION FACTOR 1ALPHA; ENDOTHELIN 3; ERYTHROPOIETIN RECEPTOR; FIBULIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUTAMATE DECARBOXYLASE; GLYOXALASE; GUANINE NUCLEOTIDE BINDING PROTEIN; INTEGRIN LINKED KINASE; LYMPHOID ENHANCER FACTOR 1; METALLOPROTEINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN KINASE C; RAS PROTEIN; RNA; SERINE PROTEINASE INHIBITOR; SOMATOMEDIN C; UNINDEXED DRUG; ZINC FINGER PROTEIN;

ALGORITHM; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; DNA PROBE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EXPRESSED SEQUENCE TAG; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SEROUS CARCINOMA; SIGNAL TRANSDUCTION; TUMOR GROWTH; UNINDEXED SEQUENCE;

CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; DNA, COMPLEMENTARY; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 4644222599     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000139646.32997.3a     Document Type: Article

References (52)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
3. Fields AL, Jones JG, Thomas GM, et al. Gynecologic Cancer. In: Lenbard RE, Osteen RT, Gansler T, eds. Clinical Oncology, 2001: 455-96.
4. Ronnett BM, Zaino RJ, Ellenson LH, et al. Endometrial Carcinoma. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 5th ed. New York: Springer-Verlag; 2002:501-60.
5. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21:33-7.
6. Duggan DJ, Bittner M, Chen Y, et al. Expression profiling using cDNA microarrays. Nat Genet 1999;21:10-4.
7. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.
8. Cheung VG, Morley M, Aguilar F, et al. Making and reading microarrays. Nat Genet 1999;21:15-9.
9. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
10. Yeoh E-J, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1: 133-43.
11. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53. K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
12. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32: 569-77.
13. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295-308.
14. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002; 33:206-12.
15. Yoshinaga K, Sasano H, Furukawa T, et al. The PTEN, BAX, and IGFIIR genes are mutated in endometrial atypical hyperplasia. Jpn J Cancer Res 1998;89:985-90.
16. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
17. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
18. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
19. Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 2000;97:3260-5.
20. Nacht M, Ferguson AT, Zhang W, et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999;59: 5464-70.
21. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003;63: 5697-702.
22. Mutter GL, Baak JP, Fitzgerald JT, et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001;83: 177-85.
23. Risinger JI, Azwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003;63:6-11.
24. Baloglu H, Cannizzaro LA, Jones JG, et al. Atypical endometrial hyperplasia shares genomic abnormalities with endometrioid carcinoma by comparative genomic hybridization. Hum Pathol 2001; 32:615-22.
25. Mutter GL, Ince TA, Baak JP, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4.
26. Dietel M. The histological diagnosis of endometrial hyperplasia. Is there a need to simplify? Virchows Arch 2001;439:604-8.
27. Faquin WC, Fitzgerald JT, Boynton KA, et al. Intratumoral genetic heterogeneity and progression of endometrioid type endometrial adenocarcinomas. Gynecol Oncol 2000;78:152-7.
28. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-7.
29. Saegusa M, Hashimura M, Yoshida T, et al. Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001;84:209-17.
30. Schlosshaur PW, Pirog EC, Levine RL, et al. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol 2000;13:1066-71.
31. Patel PS, Rawal GN, Balar DB. Combined use of serum enzyme levels as tumor markers in cervical carcinoma patients. Tumour BM 1994;15:45-51.
32. Takashi M, Sakata T, Kato K. Use of serum gamma-enolase and aldolase A in combination as markers for renal cell carcinoma. Jpn J Cancer Res 1993;84:304-9.
33. Asaka M, Kimura T, Meguro T, et al. Alteration of aldolase isozymes in serum and tissues of patients with cancer and other diseases. J Clin Lab Anal 1994;8:144-8.
34. Khan KN, Nakata K, Kusumoto Y, et al. Use of fructose 1,6-diphosphate aldolase to detect tumour necrosis after transcatheter arterial embolization of hepatocellular carcinoma. J Gastroenterol Hepatol 1998;13:192-6.
35. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1 alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001;61:6548-54.
36. Glass-Marmor L, Beitner R. Detachment of glycolytic enzymes from cytoskeleton of melanoma cells induced by calmodulin antagonists. Eur J Pharmacol 1997;328:241-8.
37. Schwartz D, Beitner R. Detachment of the glycolytic enzymes, phosphofructokinase and aldolase, from cytoskeleton of melanoma cells, induced by local anesthetics. Mol Genet Metab 2000;69: 159-64.
38. Makeh I, Thomas M, Hardelin JP, et al. Analysis of a brain-specific isozyme. Expression and chromatin structure of the rat aldolase C gene and transgenes. J Biol Chem 1994;269:4194-200.
39. Inagaki H, Eimoto T, Haimoto H, et al. Aldolase C in neuroendocrine tumors: An immunohistochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;64:297-302.
40. Davies EL, Gee JM, Cochrane RA, et al. The immunohistochemical expression of desmoplakin and its role in vivo in the progression and metastasis of breast cancer. Eur J Cancer 1999;35:902-7.
41. Depondt J, Shabana AH, Florescu-Zorila S, et al. Down-regulation of desmosomal molecules in oral and pharyngeal squamous cell carcinomas as a marker for tumour growth and distant metastasis. Eur J Oral Sci 1999;107:183-93.
42. Nei H, Saito T, Tobioka H, et al. Expression of component desmosomal proteins in uterine endometrial carcinoma and their relation to cellular differentiation. Cancer 1996;78:461-70.
43. Scandurro AB, Weldon CW, Figueroa YG, et al. Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells Int J Oncol 2001;19: 129-35.
44. Novak A, Hsu SC, Leung-Hagesteijn C, et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sd USA 1998;95:4374-9.
45. Persad S, Attwell S, Gray V, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 2000;97:3207-12.
46. D'Amico M, Hulit J, Amanatullah DF, et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 2000;275:32649-57.
47. Wu C, Keightley SY, Leung-Hagesteijn C, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem 1998;273: 528-36.
48. Tan C, Costello P, Sanghera J, et al. Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin represser, snail, in APC-/-human colon carcinoma cells. Oncogene 2001;20:133-40.
49. Troussard AA, Costello P, Yoganathan TN, et al. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 2000;19:5444-52.
50. Graff JR, Deddens JA, Konicek BW, et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res 2001;7:1987-91.
51. Bamberger AM, Bamberger CM, Wald MJ, et al. PKC isoenzyme expression and cellular responses to phorbol ester in JEG-3 choriocarcinoma cells. Endocrine 1997;6:111-6.
52. Fournier DB, Chisamore M, Lurain JR, et al. Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: Possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecol Oncol 2001;81:366-72.